{"id":"W2076863510","doi":"10.1212/wnl.78.1_meetingabstracts.s01.004","title":"Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004)","year":2012,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Alemtuzumab; Multiple sclerosis; Expanded Disability Status Scale; Glatiramer acetate; Internal medicine; Interferon beta-1a; Randomized controlled trial; Relapsing remitting; Cohort; Natalizumab; Physical therapy; Interferon beta; Transplantation; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005260091,0.001837781,0.002726696,0.0006374391,0.0004634132,0.0008799181,0.0009376885,0.002100229,0.0030969],"category_scores_gemma":[0.004072949,0.0007484686,0.002086467,0.0005096141,0.001403955,0.0008285157,0.0003619423,0.002186902,0.0004799419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009904428,"about_ca_system_score_gemma":0.001258341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006339167,"about_ca_topic_score_gemma":0.0006058915,"domain_scores_codex":[0.9970977,0.002060854,0.0001851174,0.0002632213,0.0001958387,0.0001972793],"domain_scores_gemma":[0.9966314,0.001040215,0.0009468963,0.0002511133,0.0002902339,0.0008400612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9545637,0.01478441,0.003210854,0.0003977579,0.001326666,0.00006629369,0.0000970011,0.0004611312,0.006467579,0.0000554562,0.0005513129,0.01801779],"study_design_scores_gemma":[0.724242,0.2647818,0.007887268,0.00002423906,0.0007732163,0.00009401166,0.00001617889,0.0003621724,0.001368921,0.00006408941,0.0003695413,0.00001656271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940281,0.00289701,0.0002769512,0.0001368611,0.00006318859,0.001260999,0.0004882429,0.00004554048,0.0008031484],"genre_scores_gemma":[0.9945564,0.001087029,0.0008153,0.0003920268,0.0002138671,0.001300906,0.001146624,0.00001924031,0.0004685269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005260091,"threshold_uncertainty_score":0.02781838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1050582442021715,"score_gpt":0.3401362540297446,"score_spread":0.2350780098275731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}